BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.